Eton Pharmaceutical launches ET-900 program for infantile and epileptic spasms

Eton Pharmaceutical announced a new development program, ET-900, evaluating mecasermin injection for the treatment of infantile and epileptic spasms, with plans to dose the first patient in Q1 2027.

Detected & updated continuously · Source: Nebula